指南与共识消化道肿瘤与早癌消化内镜

早发性结直肠癌德尔菲倡议(DIRECt)国际管理指南

Delphi Initiative for Early-Onset Colorectal Cancer (DIRECt) International Management Guidelines.
指南 / 共识 · Clin Gastroenterol Hepatol · 2022-12-20

由69名专家组成的国际多学科DIRECt小组采用德尔菲法,经3轮投票(共识≥80%)制定首部早发性结直肠癌循证共识推荐,共31条声明覆盖诊断、危险因素、遗传学、病理肿瘤学、内镜、治疗和支持照护7个领域。

要点

  • 所有50岁以下个体应进行结直肠癌风险分层并及时评估症状。
  • 所有新诊断早发性结直肠癌患者应接受胚系基因检测,理想情况下在手术前。
  • 基于当前证据,早发性结直肠癌的内镜、手术和肿瘤治疗不应不同于晚发性结直肠癌,但携带致病或可能致病胚系变异者除外。

核心结论

  • DIRECt小组制定了首部关于早发性结直肠癌的共识推荐,所有声明应结合随附评论和文献综述一并考虑。
  • 该小组强调了应优先开展研究的领域,这些指南是临床医生照护早发性结直肠癌患者的有用工具。

研究设计与样本

  • 由69名专家组成的国际多学科小组(DIRECt)在回顾已发表文献后,采用德尔菲法起草并回答临床相关问题。
  • 每条声明经过3轮投票,达到≥80%的共识同意水平。

主要发现

  • DIRECt小组在7个领域共产生31条声明:诊断、危险因素、遗传学、病理肿瘤学、内镜、治疗和支持照护。
  • 强烈共识认为所有50岁以下个体应接受结直肠癌风险分层并及时评估症状。
  • 所有新诊断早发性结直肠癌患者应接受胚系基因检测,理想情况下在手术前。
  • 基于当前证据,早发性结直肠癌的内镜、手术和肿瘤治疗不应不同于晚发性结直肠癌,但携带致病或可能致病胚系变异者除外。
  • 关于化疗的证据不足以推荐改变现有治疗方案;生育力保护和性健康对早发性结直肠癌幸存者很重要。

关键数值与推荐

  • 共识定义为≥80%的同意水平,每条声明经3轮投票。
  • 所有50岁以下个体应接受结直肠癌风险分层并及时评估症状(强烈共识)。
  • 所有新诊断早发性结直肠癌患者应接受胚系基因检测,理想情况下在手术前。
  • 早发性结直肠癌的内镜、手术和肿瘤治疗不应不同于晚发性结直肠癌,但携带致病或可能致病胚系变异者除外。
  • 关于化疗的证据不足以推荐改变现有治疗方案。

临床怎么用

  • 临床医生应将本共识推荐与随附评论和文献综述结合使用,以照护早发性结直肠癌患者。
  • 对50岁以下个体进行结直肠癌风险分层并及时评估症状。
  • 对新诊断早发性结直肠癌患者在手术前(理想情况下)进行胚系基因检测。
  • 早发性结直肠癌的内镜、手术和肿瘤治疗不应不同于晚发性结直肠癌,但携带致病或可能致病胚系变异者除外。
  • 关注早发性结直肠癌幸存者的生育力保护和性健康。

局限性

  • DIRECt小组强调了存在知识空白的领域,应作为未来研究的优先方向,包括一般人群首次筛查年龄、粪便免疫化学检测的使用、化疗、内镜治疗以及早发性结直肠癌患者的治疗后监测。
  • 关于化疗的证据不足以推荐改变现有治疗方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Patients with early-onset colorectal cancer (eoCRC) are managed according to guidelines that are not age-specific. A multidisciplinary international group (DIRECt), composed of 69 experts, was convened to develop the first evidence-based consensus recommendations for eoCRC. METHODS: After reviewing the published literature, a Delphi methodology was used to draft and respond to clinically relevant questions. Each statement underwent 3 rounds of voting and reached a consensus level of agreement of ≥80%. RESULTS: The DIRECt group produced 31 statements in 7 areas of interest: diagnosis, risk factors, genetics, pathology-oncology, endoscopy, therapy, and supportive care. There was strong consensus that all individuals younger than 50 should undergo CRC risk stratification and prompt symptom assessment. All newly diagnosed eoCRC patients should receive germline genetic testing, ideally before surgery. On the basis of current evidence, endoscopic, surgical, and oncologic treatment of eoCRC should not differ from later-onset CRC, except for individuals with pathogenic or likely pathogenic germline variants. The evidence on chemotherapy is not sufficient to recommend changes to established therapeutic protocols. Fertility preservation and sexual health are important to address in eoCRC survivors. The DIRECt group highlighted areas with knowledge gaps that should be prioritized in future research efforts, including age at first screening for the general population, use of fecal immunochemical tests, chemotherapy, endoscopic therapy, and post-treatment surveillance for eoCRC patients. CONCLUSIONS: The DIRECt group produced the first consensus recommendations on eoCRC. All statements should be considered together with the accompanying comments and literature reviews. We highlighted areas where research should be prioritized. These guidelines represent a useful tool for clinicians caring for patients with eoCRC.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Cavestro GM, Mannucci A, Balaguer F, et al. Delphi Initiative for Early-Onset Colorectal Cancer (DIRECt) International Management Guidelines. Clin Gastroenterol Hepatol. 2022. PMID: 36549470. doi:10.1016/j.cgh.2022.12.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。